Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
HTG Molecular Diagnostics, Inc is a diagnostics & research business based in the US. HTG Molecular Diagnostics shares (HTGM) are listed on the NASDAQ and all prices are listed in US Dollars. HTG Molecular Diagnostics employs 108 staff and has a trailing 12-month revenue of around USD$10.8 million.
|Latest market close||USD$0.276|
|52-week range||USD$3.78 - USD$13.8|
|50-day moving average||USD$4.9262|
|200-day moving average||USD$6.6936|
|Wall St. target price||USD$12.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.6|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-95.75%|
|1 month (2020-12-17)||-94.46%|
|3 months (2020-10-16)||-15.34%|
|6 months (2020-07-16)||-52.94%|
|1 year (2020-01-16)||-58.81%|
|2 years (2019-01-16)||-87.79%|
|3 years (2018-01-16)||3.5|
|5 years (2016-01-15)||4.21|
|Revenue TTM||USD$10.8 million|
|Gross profit TTM||USD$-277,709|
|Return on assets TTM||-28.35%|
|Return on equity TTM||-94.63%|
|Market capitalisation||USD$23.1 million|
TTM: trailing 12 months
There are currently 120,329 HTG Molecular Diagnostics shares held short by investors – that's known as HTG Molecular Diagnostics's "short interest". This figure is 10.6% up from 108,785 last month.
There are a few different ways that this level of interest in shorting HTG Molecular Diagnostics shares can be evaluated.
HTG Molecular Diagnostics's "short interest ratio" (SIR) is the quantity of HTG Molecular Diagnostics shares currently shorted divided by the average quantity of HTG Molecular Diagnostics shares traded daily (recently around 143248.80952381). HTG Molecular Diagnostics's SIR currently stands at 0.84. In other words for every 100,000 HTG Molecular Diagnostics shares traded daily on the market, roughly 840 shares are currently held short.
However HTG Molecular Diagnostics's short interest can also be evaluated against the total number of HTG Molecular Diagnostics shares, or, against the total number of tradable HTG Molecular Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case HTG Molecular Diagnostics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 HTG Molecular Diagnostics shares in existence, roughly 50 shares are currently held short) or 0.0499% of the tradable shares (for every 100,000 tradable HTG Molecular Diagnostics shares, roughly 50 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against HTG Molecular Diagnostics.
Find out more about how you can short HTG Molecular Diagnostics stock.
We're not expecting HTG Molecular Diagnostics to pay a dividend over the next 12 months.
HTG Molecular Diagnostics's shares were split on a 1:15 basis on 23 November 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your HTG Molecular Diagnostics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for HTG Molecular Diagnostics shares which in turn could have impacted HTG Molecular Diagnostics's share price.
Over the last 12 months, HTG Molecular Diagnostics's shares have ranged in value from as little as $3.78 up to $13.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HTG Molecular Diagnostics's is 1.6824. This would suggest that HTG Molecular Diagnostics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq path assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq ALKPlus assay EU;HTG EdgeSeq precision immuno-oncology panel; HTG lung fusions assay; HTG autoimmune panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.